Constantine Alifrangis

Constantine Alifrangis

Auto-generated profile, based on publicly available information

Constantine Alifrangis

Department of Medical Oncology University College London Hospitals NHS Foundation Trust London UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JWJonathan Wan
Jonathan Wan
KHKatrin Heider
Katrin Heider
DGDavina Gale
Davina Gale
SMSuzanne Murphy
Suzanne Murphy
EFEyal Fisher
Eyal Fisher
NRNitzan Rosenfeld
Nitzan Rosenfeld
Circulating tumor-derived DNA (ctDNA) can be used to monitor cancer dynamics noninvasively. Detection of ctDNA can be challenging in patients with low-volume or residual disease, where plasma contains very few tumor-derived DNA fragments. We show that sensitivity for ctDNA detection in plasma can be improved by analyzing hundreds to thousands of mutations that are first identified by tumor genotyping. We describe the INtegration of VAriant Reads (INVAR) pipeline, which combines custom error-suppression methods and signal-enrichment approaches based on biological features of ctDNA. With this approach, the detection limit in each sample can be estimated independently based on the number of informative reads sequenced across multiple patient-specific loci. We applied INVAR to custom hybrid-capture sequencing data from 176 plasma samples from 105 patients with melanoma, lung, renal, glioma, and breast cancer across both early and advanced disease. By integrating signal across a median of >105 informative reads, ctDNA was routinely quantified to 1 mutant molecule per 100,000, and in some cases with high tumor mutation burden and/or plasma input material, to parts per million. This resulted in median area under the curve (AUC) values of 0.98 in advanced cancers and 0.80 in early-stage and challenging settings for ctDNA detection. We generalized this method to whole-exome and whole-genome sequencing, showing that INVAR may be applied without requiring personalized sequencing panels so long as a tumor mutation list is available. As tumor sequencing becomes increasingly performed, such methods for personalized cancer monitoring may enhance the sensitivity of cancer liquid biopsies.

18 January 2018 in eLife
Verified
Journal Article
Open access
KKKrishna Kalyan Kolluri
Krishna Kalyan Kolluri
CAConstantine Alifrangis
Constantine Alifrangis
NKNeelam Kumar
Neelam Kumar
YIYuki Ishii
Yuki Ishii
SPStacey Price
Stacey Price
SJSamuel M Janes
Samuel M Janes
Malignant mesothelioma (MM) is poorly responsive to systemic cytotoxic chemotherapy and invariably fatal. Here we describe a screen of 94 drugs in 15 exome-sequenced MM lines and the discovery of a subset defined by loss of function of the nuclear deubiquitinase BRCA associated protein-1 (BAP1) that demonstrate heightened sensitivity to TRAIL (tumour necrosis factor-related apoptosis-inducing ligand). This association is observed across human early passage MM cultures, mouse xenografts and human tumour explants. We demonstrate that BAP1 deubiquitinase activity and its association with ASXL1 to form the Polycomb repressive deubiquitinase complex (PR-DUB) impacts TRAIL sensitivity implicating transcriptional modulation as an underlying mechanism. Death receptor agonists are well-tolerated anti-cancer agents demonstrating limited therapeutic benefit in trials without a targeting biomarker. We identify BAP1 loss-of-function mutations, which are frequent in MM, as a potential genomic stratification tool for TRAIL sensitivity with immediate and actionable therapeutic implications.

1 March 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
CAConstantine Alifrangis
Constantine Alifrangis
ASAnand Sharma
Anand Sharma
SCShafi Chowdhury
Shafi Chowdhury
SDSarah Duncan
Sarah Duncan
Marina MilicMarina Milic
Marina Milic
SSShamash Shamash
Shamash Shamash

21 September 2022 in BJU International
Verified
Journal Article
Closed access
SWShafi Wardak
Shafi Wardak
KPKarl Pang
Karl Pang
FCFabio Castiglione
Fabio Castiglione
JLJamie Lindsay
Jamie Lindsay
MWMiles Walkden
Miles Walkden
AMAsif Muneer
Asif Muneer

7 March 2023 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
GWGeorgina E. Wood
Georgina E. Wood
FCFlorence Chamberlain
Florence Chamberlain
BTBen Tran
Ben Tran
CCCiara Conduit
Ciara Conduit
ELElizabeth Liow
Elizabeth Liow
PRPrabhakar Rajan
Prabhakar Rajan

13 September 2019 in Anticancer Research
Verified
Journal Article
Open access
PDF file
ASAnand Sharma
Anand Sharma
CAConstantine Alifrangis
Constantine Alifrangis
Marina MilicMarina Milic
Marina Milic
Marcia HallMarcia Hall
Marcia Hall
NVNikhil Vasdev
Nikhil Vasdev
JSJonathan Shamash
Jonathan Shamash
Background/Aim: The occurrence of somatic transformation in germ cell tumour (GCT) is rare, with increased incidence in teratomatous tumours. The aim of this study was to understand the clinical outcomes of patients with metastatic GCT with somatic transformation. Materials and Methods: A retrospective study was conducted in two tertiary cancer centres in London. Between 1998 and 2016, 30 cases of somatic transformation in GCT treated at the Mount Vernon Cancer Centre and St. Bartholomew's Hospital were identified. The median age at diagnosis was 34 years (range=18-56 years). The histological diagnosis at transformation was rhabdomyosarcoma, sarcomatoid yolk sac, sarcoma (non-specified), clear cell carcinoma, adenocarcinoma and primitive neuro ectodermal tumour (PNET). Results: The 5-year survival rate of all patients was 47%, and that of patients with testicular primary (n=26 patients) was 37%. Conclusion: Somatic transformation component in testicular GCTs is generally considered to be an adverse prognostic factor, however, a reasonable 5-year overall survival rate (87.5%) was observed in patients who present with this at first diagnosis.